A study to assess hepatic steatosis and fibrosis in chronic hepatitis B patients with the help of non-invasive tests
DOI:
https://doi.org/10.71152/ajms.v16i7.4568Keywords:
Chronic hepatitis B; Hepatic fibrosis; Hepatic steatosis; APRI; Fibrosis-4; FibroScan; Controlled attenuation parameter; Non-invasive tests; Hepatitis B virus DNA; Liver stiffness measurementAbstract
Background: Chronic hepatitis B (CHB) is a persistent global health issue, frequently leading to hepatic fibrosis and steatosis. Although liver biopsy remains the diagnostic benchmark, its invasiveness necessitates safer alternatives. Non-invasive methods such as FibroScan, aspartate transaminase to platelet ratio index (APRI), and Fibrosis-4 (FIB-4) scores have shown promise in assessing liver pathology.
Aims and Objectives: To evaluate the diagnostic performance of APRI, FIB-4, and FibroScan in detecting hepatic fibrosis and steatosis in CHB patients and their correlation with biochemical and virological parameters.
Materials and Methods: This cross-sectional study was conducted at Maharani Laxmi Bai Medical College, Jhansi, from January 2023 to June 2024. A total of 112 patients with CHB were enrolled. Liver stiffness and steatosis were assessed using FibroScan and controlled attenuation parameters. APRI and FIB-4 scores were calculated, and laboratory values, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and hepatitis B virus (HBV) DNA, were analyzed.
Results: Advanced FIB-4 was observed in 42 patients (37.50%) and severe steatosis (S3) in 41 patients (36.60%). Elevated AST levels (>2×upper limit of normal) were found in 54 patients (48.21%) and ALT in 57 patients (50.89%). High HBV DNA levels (>20,000 IU/mL) were present in 59 patients (52.67%). APRI score >1.5 showed a sensitivity of 85.71% and specificity of 79.55% (area under the curve [AUC]: 0.837), whereas FIB-4 score >3.25 had a sensitivity of 64.29% and specificity of 85.37% (AUC: 0.815). Both scores showed limited utility in detecting steatosis.
Conclusion: FibroScan, APRI, and FIB-4 are effective non-invasive tools for assessing hepatic fibrosis in CHB patients. They offer viable alternatives to biopsy, especially in settings with limited resources.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
